Table 1.
Baseline characteristics of 336 patients with advanced-stage natural killer/T-cell lymphoma.
| Characteristic | Number (%) | P value* | |||
|---|---|---|---|---|---|
| Total | Asp-containing regimen cohort | Non-Asp-containing regimen cohort | Unknown regimen cohort | ||
| Sex | 0.008 | ||||
| Male | 238 (70.8) | 109 (74.7) | 73 (60.8) | 56 (80.0) | |
| Female | 98 (29.2) | 37 (25.3) | 47 (39.2) | 14 (20.0) | |
| Age | 0.690 | ||||
| ≤60 years | 297 (88.4) | 131 (89.7) | 106 (88.3) | 60 (85.7) | |
| >60 years | 39 (11.6) | 15 (10.3) | 14 (11.7) | 10 (14.3) | |
| Stage | 0.141 | ||||
| III | 11 (3.3) | 3 (2.1) | 7 (5.8) | 1 (1.4) | |
| IV | 325 (96.7) | 143 (97.9) | 113 (94.2) | 69 (98.6) | |
| ECOG PS | 0.178 | ||||
| 0–1 | 260 (77.4) | 120 (82.2) | 89 (74.2) | 51 (72.9) | |
| 2–4 | 76 (22.6) | 26 (17.8) | 31 (25.8) | 19 (27.1) | |
| Elevated LDH | 0.337 | ||||
| Yes | 178 (53.0) | 72 (49.3) | 64 (53.3) | 42 (60.0) | |
| No | 158 (47.0) | 74 (50.7) | 56 (46.7) | 28 (40.0) | |
| B symptoms | 0.889 | ||||
| Yes | 184 (54.8) | 82 (56.2) | 65 (54.2) | 37 (52.9) | |
| No | 152 (45.2) | 64 (43.8) | 55 (45.8) | 33 (47.1) | |
| Extranodal involvement >1 | 0.032 | ||||
| Yes | 257 (76.5) | 121 (82.9) | 83 (69.2) | 53 (75.7) | |
| No | 79 (23.5) | 25 (17.1) | 37 (30.8) | 17 (24.3) | |
| NRI risk stratification | 0.187 | ||||
| Low | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Intermediate high | 45 (13.4) | 21 (14.4) | 20 (16.7) | 4 (5.7) | |
| High | 129 (38.4) | 53 (36.3) | 49 (40.8) | 27 (38.6) | |
| Very high | 162 (48.2) | 72 (49.3) | 51 (42.5) | 39 (55.7) | |
ECOG PS, Eastern Clinical Oncology Group performance status; LDH, lactate dehydrogenase; NRI, nomogram-revised risk index.
*Comparison of the difference among the Asp-containing, non-Asp containing, and unknown regimen cohorts.